AADI - Aadi Bioscience, Inc.
IEX Last Trade
1.87
0 0%
Share volume: 0
Last Updated: Fri 20 Dec 2024 09:24:15 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.46%
PREVIOUS CLOSE
CHG
CHG%
$1.87
0.67
0.26%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-2.52%
1 Month
4.50%
3 Months
20.21%
6 Months
42.33%
1 Year
12.62%
2 Year
-81.14%
Key data
Stock price
$1.87
DAY RANGE
$1.87 - $2.54
52 WEEK RANGE
$1.41 - $2.63
52 WEEK CHANGE
$17.77
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Neil P. Desai
Region: US
Website: aadibio.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: aadibio.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin.
Recent news